 |
|
|
| |
Relative Bioavailability of a Dolutegravir (DTG) Dispersible Tablet and the Effect of Low and High Mineral Content Water on the Tablet in Healthy Adult Volunteers
|
| |
| |
Reported by Jules Levin
IAS 2015 Vancouver July 19-23
S Weller,1 F Jerva,1 A Buchanan,1 M Holton,1 I Conn,1 M Choukour,2 J Borland,1 I Song1
1GlaxoSmithKline, Research Triangle Park, NC, USA; 2PAREXEL, Waltham, MA, USA
IAS: Safety and Efficacy of DTG by Age, Race and Gender: Subgroup Analysis of 96 Week Results From Treatment-Naive Patients in Phase III Trials (SPRING-2 [ING113086], SINGLE [ING114467] and FLAMINGO [ING114915]) - (07/24/15)
Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents......
https://clinicaltrials.gov/ct2/show/NCT01302847
|
| |
|
|
|
|
|
